1. Center for Drug Evaluation and Research (2010) Guidance for industry. Patient-reported outcome measures: Use in medical product development to support labeling claims. US Department of Health and Human Services, Food and Drug Administration. December 2009. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf . Accessed July 1, 2010.
2. Fayers, P., & Hays, R. (Eds.). (2005). Assessing quality of life in clinical trials: Methods and practice (2nd ed.). New York: Oxford University Press.
3. Retsch-Bogart, G. Z., Quittner, A. L., Gibson, R. L., Oermann, C. M., McCoy, K. S., Montgomery, A. B., et al. (2009). Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest, 135(5), 1223–1232.
4. Goss, C. H., & Quittner, A. L. (2007). Patient-reported outcomes in cystic fibrosis. Proceedings of the American Thoracic Society, 4(4), 378–386.
5. Quittner, A. L., Modi, A., & Cruz, I. (2008). Systematic review of health-related quality of life measures for children with respiratory conditions. Paediatric Respiratory Reviews, 9(3), 220–232.